Purpose Clinical pharmacist (CP) interventions from the PROTECTED-UK cohort, a multi-site critical care interventions study, were further analysed to assess effects of: time on critical care, number of interventions, CP expertise and days of week, on impact of intervention and ultimately contribution to patient care. Methods Intervention data were collected from 21 adult critical care units over 14 days. Interventions could be error, optimisation or consults, and were blind-coded to ensure consistency, prior to bivariate analysis. Pharmacy service demographics were further collated by investigator survey. Key findings Of the 20 758 prescriptions reviewed, 3375 interventions were made (intervention rate 16.1%). CPs spent 3.5 h per day (mean, AESD 1.7) on direct patient care, reviewed 10.3 patients per day (AESD 4.2) and required 22.5 min (AESD 9.5) per review. Intervention rate had a moderate inverse correlation with the time the pharmacist spent on critical care (P = 0.05; r = 0.4). Optimisation rate had a strong inverse association with total number of prescriptions reviewed per day (P = 0.001; r = 0.7). A consultant CP had a moderate inverse correlation with number of errors identified (P = 0.008; r = 0.6). No correlation existed between the presence of electronic prescribing in critical care and any intervention rate. Few centres provided weekend services, although the intervention rate was significantly higher on weekends than weekdays. Conclusions A CP is essential for safe and optimised patient medication therapy; an extended and developed pharmacy service is expected to reduce errors. CP services should be adequately staffed to enable adequate time for prescription review and maximal therapy optimisation.
Introduction
Critical care is a high-risk medication area where vulnerable, acutely unwell patients are treated with intense therapies in a complex environment. In addition to critical illness, patients are often older and have multiple co-morbidities. [1] The presence of multiple organ failure adds to the complexity of medication regimens in the individual patient. There is both a high rate of parenterally administered medication and a high risk of prescribing error. The frequent lack of mental capacity of patients prevents them contributing to medication reviews or taking responsibility for medicines administration, and increases their vulnerability to erroneous or suboptimal medication therapy.
There is much evidence to support the need for clinical pharmacists (CPs) in the care of critically ill patients. CPs have been demonstrated as essential to improving medicines safety both at an individual and a broader critical care organisational level. [2] [3] [4] [5] There is also a wealth of evidence existing to demonstrate the value of CPs in critical care, showing a significant positive impact on patient care, particularly in relation to improved safety, medicines optimisation, reduced expenditure and reduced length of stay. [6] [7] [8] [9] Pharmacist interventions include identification of 'errors' (rectification of incorrect prescribing, including omissions), 'optimisation' (the enhancement of a patient's medication to improve efficacy of therapy) or a 'consult' (reactive provision of advice to a healthcare professional regarding a specific issue). [10] While, anecdotally, many hospitals collect intervention data from their pharmacy teams, this is rarely analysed in depth and, to the best of our knowledge, there has been no large-scale multisite study collecting and reviewing CP interventions in critical care. The Expert Practice Development Group (EPDG) of the United Kingdom Clinical Pharmacy Association (UKCPA) is composed of pharmacists with expertise in critical care. In 2011, the EPDG undertook to collaborate on the first multisite study relating to CP activity, comprising 21 adult critical care units. In 2012, this study became known as PROTECTED-UK (Pharmacist's Review and Outcomes: Treatment Enhancing Contributions Tallied, Evaluated and Documented); the study's key results were published in 2015. [11] It demonstrated that CP interventions were made in nearly one in six of all prescriptions reviewed, and that two-thirds of these interventions were of moderate or high clinical impact. A prescription is defined as a single item prescribed; therefore, review of a patient may include multiple prescriptions. Of these interventions, 2953 (87.1%) were proactive, where the intervention was identified by the CP without prior involvement of a healthcare professional. The breakdown of intervention type was 6.8% error, 8.3% optimisation and 1% consultation, of all prescriptions reviewed. The great majority of interventions -2967 (87.5%) -were accepted by the interprofessional team.
This publication did not describe the nature of the CP intervention, the characteristics of the clinical pharmacy service and how these relate to patient care.
The recent Faculty of Intensive Medicine (FICM) and Intensive Care Society (ICS) standards on staffing specifies daily input of the pharmacist on the interprofessional ward round, ideally provided 7 days a week. [12] Despite these standards, earlier national surveys have demonstrated that provision of pharmacy services varies among hospitals in the UK, both in terms of pharmacist-topatient bed ratio, level of expertise of the CP providing the service [13] and degree of weekend service provision. Few UK adult critical care units have a proactive weekend pharmacy service, with the majority providing a reactive, on-call service.
The FICM/ICS standards state that sole pharmacist practitioners on critical care should be of an Advanced Stage II standard (Table 1) . If the practitioners work as a team, there should be a range of CPs (from Foundation to Mastery), including the support of clinical pharmacy technicians. These levels of expertise correlate to the recently introduced (UK) Royal Pharmaceutical Society's Faculty accreditation system for post-Foundation training [14] which provides a quality assured credentialing system. Pharmacists are now able to provide evidence to support a credential at advance practice Stage I, Stage II or Fellowship. Prior to this national initiative (and during the study period) -which continues to be rolled out to the workforce -defining level of practice remains a challenge. Consequently, pharmacist grade, according to National Health Service (NHS) Agenda for Change banding, is often used as a surrogate indicator of level of practice, despite clear limitations (Table 1) . While the expectation might be that the greater the expertise of the pharmacist, the higher the impact of the intervention, there is a lack of corroborating evidence to date.
The aim of this paper was to determine the factors affecting the interventions made, specifically examining the relationships between:
Intervention and grade of pharmacy staff Number of prescriptions reviewed and demographics of the service provided within the hospital, including number of patient beds, ward round attendance, pharmacist prescribers Day of the week intervention were made.
Method
PROTECTED-UK was a prospective descriptive study of self-reported clinical interventions undertaken by pharmacy staff, conducted in 21 adult critical care units across the UK over a 14 day period from 5th to 18th November 2012, capturing all interventions reported by the critical care pharmacy team. The trial period of 14 days was chosen as a balance of pragmatism, with the inclusion of at least 2 weekends and within a calendar period, where annual leave or calendar events were least likely to influence the data capture. An online survey was developed to record pharmacist and pharmacy service demographics of the study site. All members of the EPDG were encouraged to participate in this study. A detailed description of the methodology and site demographics has been described previously. [11] Interventions Interventions were defined as contributions to care aimed at improving patient care, and classified as an 'error' (a medication error was defined as an error in the process of prescribing, dispensing, preparing, administering, monitoring or providing medicine advice, regardless of whether harm has occurred, [2, 15] 'optimisation' (defined as a proactive contribution that sought to enhance patient care) or a 'consult' (reactive intervention in response to a request from a member of the MDT for an CP review). At each site, each critical care pharmacy team member recorded their interventions, which occurred as a result of the clinical pharmacy review that they provided as part of their routine clinical service. All intervention data were recorded on a bespoke password-protected web portal database in real time, with all identifiable patient specific data anonymised. The details recorded included a short description of the intervention, medication involved, type of intervention, grade of clinical impact as decided by reporting pharmacist, acceptance rate and patient outcome (positive or negative). Each intervention included the grade of pharmacy staff involved. This data was exported into SPSS version 22 (IBM) from an SQL file. SPSS data file was examined for variable correspondence with the SQL file. Coding of the data, investigating missing data and clarification of ambiguous data were undertaken.
The activity data of the clinical pharmacy team were also recorded in the web-portal, daily, in terms of time involved in clinical activity, and numbers of patients and prescriptions reviewed. Practitioners were provided with definitions and supporting 'help files' on the web-portal. To address data consistency, data entry fields were format locked to reduce typographical entries or field input errors. The web-portal itself, the field entry formats and the on-screen form layout were piloted before start of the study period.
To assess relevant denominators, the following data sets were recorded: the number of medication orders (new prescriptions) reviewed each day (on day one, all medication orders were regarded as new) and the number of patients reviewed. The type of intervention was characterised according to a previously used classification. [16] The proportion of interventions accepted by the team (or self-prescribed by independent prescriber pharmacists) was also recorded.
Clinical Impact Coding
Each intervention was graded for potential clinical impact to patient care. The ordinal scale utilised is well established to grade medication errors. [2] The optimisation and consult scale were specifically developed for PRO-TECTED-UK, to mirror the errors scale i.e. low, moderate, high and life-saving impact.
All collated interventions were blind-graded by one of the principal investigators, a CP, for the purposes of consistency. Where the grading was the same as the recording pharmacist, this was considered the final grade. If there was a difference, the intervention was blind-graded by one of two consultant pharmacist investigators. Where these two grades agreed, this was considered the final grade. If all three grades disagreed, then a critical care consultant physician blind-graded the intervention and the final grade was where two grades agreed.
Pharmacy and Critical Care Service Survey
Following intervention data collection, an online survey was designed using www.surveymonkey.co.uk in order to record the demographics of each of the participating units and clinical pharmacy teams. The number, grade of CP, and whether a consultant pharmacist led the team were recorded. Further data included: type of unit (general or specialist); utilisation of electronic prescribing; 'developed' (defined as more than one practitioner in the team) or 'undeveloped' pharmacy service; the presence, scope and grade of independent prescriber; presence of a weekend clinical pharmacy service, and finally the method of communication back to the interprofessional team (team meeting, self-prescribed interventions, individual feedback to junior doctors, bedside ward round or 'other').
Analysis
Bivariate analysis was conducted using SPSS version 22 (IBM). The data were analysed for central tendency. Multiple regression was not feasible as many of the factors were not independent factors. A P value <0.05 was considered statistically significant, and the correlation coefficients (r values) were reported as an indication of the strength and direction of the relationship between the factors analysed. Chi test was used for explore the relationship between pharmacy staff grading and intervention rate.
The intervention rate was defined as the number of interventions divided by the number of prescriptions reviewed. The same calculation was applied to error rate, optimisation rate and consult rate. The rate of each intervention type was then checked for correlation against the pharmacy and critical care service factors.
Ethical Considerations
The study was deemed a clinical audit after with discussion with Research and Development (R&D) at University College London (UCL), the lead site, and the need for ethics approval was waived. It was consequently registered as a clinical audit at each participating site, in line with local requirements.
Results
The majority of results were analysed solely on the weekday data. The weekend intervention numbers were relatively low and reported separately. A breakdown of individual unit activity is provided (Table 2) .
Time Spent on Prescription Review
The mean time spent on the ward per pharmacist was 3.5 h per day (AESD 1.7). Each pharmacist reviewed a mean of 10.3 patients per day (AESD 4.2), and spent 22.5 (AESD 9.5) min per patient review. A mean of 1.2 (AESD 0.6) interventions were made per patient seen. The intervention rate had a moderate inverse correlation with both the number of prescriptions reviewed and the total number of patients reviewed daily (P = 0.02, r = À0.5 and P = 0.02, r = À0.5) respectively. The length of time the pharmacist spent on the ward also had a moderate inverse correlation with the intervention rate (P = 0.05, r = À0.4). There was a strong inverse correlation between the optimisation rate and daily prescriptions reviewed (P = 0.001, r = À0.7) and a moderate inverse association with the total number of patients reviewed daily (P = 0.02, r = À0.5).
Weekday and Weekend Service Provision
When weekdays were broken down into individual days, Monday had the highest intervention rate (24.1%) and Friday the lowest (17.0%). The greatest number of patients were reviewed on a Monday, as well as a statistically significantly greater number of new drug orders were reviewed (P = 0.038). The total pharmacy time spent reviewing patients on the ward was similar across all weekdays with a mean of 5.7 h (AESD = 0.19).
Of the 21 units with a proactive clinical pharmacy service, only two provided a specialist service at weekends (Saturdays only, at the time of the study), with the other units predominantly providing an on-call, reactive service for emergencies, or a dispensary-based service. A greater intervention rate was seen on weekends compared with weekdays (Table 3) ; 33.6% and 16.1% respectively (P < 0.0001). Of the weekend interventions, the majority (89%) were optimisations, with 83.9% of moderate or high clinical impact. Five of the units without a specialist weekend service also recorded interventions; 15 in total. These were from dispensary or on-call shifts. At weekends, there is a lower than expected frequency of errors (4.2% at weekends against 42.3% on weekdays, v 2 = 56.59 P < 0.0001) and a peak in error reporting on Mondays.
Regarding impact scoring, overall, there was disagreement in 1655 (49.0%) of cases after the first independent review, which resolved to 110 (3.3%) of cases of disagreement following a second round assessment before consensus.
Grade of Pharmacist
The relationship between the grade of pharmacist and interventions made was also investigated, however, the correlation between impact of intervention and grade of pharmacist was not. The presence of a consultant pharmacist had a moderate inverse correlation with the error rate detection of the unit (P = 0.008, r = À0.6). An explanation of UK pharmacist gradings can be found in Table 1 . Consultant pharmacists made the most interventions per prescription reviewed (22.6%), followed by pharmacy technicians (17.6%) whose interventions were in relation to medicines reconciliation (Table 4) . Consultant pharmacists were also more likely to intervene in the form of a consult. Junior pharmacists (Band 6) made the lowest number of interventions per prescription reviewed (11.1%). Band 8a pharmacists reviewed the most prescriptions, with a total of 7825 items, and had an intervention rate of 15.0% (P < 0.0001, v 2 = 37.7).
Other Factors
There was no correlation between the presence of electronic prescribing on the critical care unit and any of the intervention rates. This was also found for 'developed/undeveloped pharmacy team' and specialised versus general units. However, moderate positive associations were found for the presence of non-medical prescribing (excluding pharmacist prescribers) and overall intervention rate and optimisation rate (P = 0.04, r = 0.5 and P = 0.02, r = 0.5 respectively).
Discussion
The study results demonstrate the clinical impact CPs routinely have on patient care in critical care units. As described in the earlier paper, there was a mean intervention rate of one intervention per six prescriptions reviewed. [11] None of the sites that participated in PRO-TECTED-UK had an intervention rate of zero. This could imply that hospitals in the UK that do not provide a clinical pharmacy service to their critical care units could be compromising patient care by not facilitating daily CP review. This is the first UK multisite study exploring the interventions made by CPs in critical care. The size of the study enabled in-depth analysis of the types of interventions made, including an exploration of the relationships between the units' demographics and the results.
The units involved in the study were heterogeneous, with a wide range of pharmacy expertise, pharmacist-topatient-bed ratios, patient illness severities and different types of pharmacy service provided. A number of hospitals were treated as a single unit while others, with multiple sites, reported each separately. Interventions were reported and graded by the individual pharmacists on the units, which may cause variation in data collection and bias due to self-reporting. However, the moderation process should have addressed some of the variation. There is a potential for under-reporting and recall bias, although the majority of interventions were recorded close to the time of intervention and should have minimised this. Units self-defined as 'developed/undeveloped' may represent a simplistic assessment of the resources available which may reduce medication errors in practice.
Intervention rates were inversely correlated with the number of prescriptions and patients the pharmacist reviewed. As far as we are aware, this is the first piece of work to demonstrate that CP review takes time, and that to achieve full effect from a clinical pharmacy service, providers must ensure that units are adequately staffed.
Error rates also inversely correlated with the presence of a consultant pharmacist, which could suggest the presence of a consultant pharmacist leads to more effective prescribing error reduction, although given the low numbers of these posts within UK critical care, results are hard to extrapolate conclusively. A recent review found that pharmacists had no significant impact on general medication error reduction, however, they were more likely to reduce preventable errors. [17] An accompanying editorial suggests that CP impact on patient care is related to experience and clinical training, supporting the results found in our study. [18] In terms of pharmacist grade, as a pharmacist's knowledge and skills increase, it is expected that their role in critical care will change in a more proactive way, with more consultations, optimisations and overall higher impact intervention, which is demonstrated in the reported data. A lower intervention rate was observed with junior pharmacists. This could be attributed to their limited specialist knowledge. Contrary to this was the observation that pharmacy technicians had the second highest intervention rate after consultant pharmacists, 88.2% of these were in medicines reconciliation. This clearly demonstrates their review of medication on admission and the meticulous attention to detail they take in getting the medicines reconciliation right. A lower intervention numbers recorded by consultant pharmacists is likely to be reflective of their more advisory role, rather than routine daily patient review. These data also supports the ICS staffing recommendations that sole practitioners should be of at least an 8a level and pharmacists working in teams should reflect a skill mix, preferably led by a consultant pharmacist in larger centres. [19] The role of a consultant pharmacist in this capacity will generally provide leadership, conduct research, develop the service and oversee the pharmacy service.
The data suggest that for a nine-bedded critical care unit, a CP needs at least 3 h of clinical time to effectively review all patients, producing an intervention rate of 1.16 interventions per patient reviewed. This is in line with ICS standards which recommend 0.1 whole time equivalent (WTE) of a CP for level 3 patients, and 0.05 WTE for level 2 patients. Importantly, the data do not distinguish differences between the length of time needed to review a level 3 patient, and level 2 patient. One would anticipate that a longer review time would be needed for sicker patients, due to their complexity, both in terms of medication and co-morbidities.
In addition, increased time is needed at both admission and discharge; admission, in order to fully review the patient and undertake medicines reconciliation and discharge, to ensure that medications have been reviewed and appropriately discontinued or reinitiated. [19] In units currently understaffed with CPs, consideration should be given to increase staffing to national ICS standards, which would be expected to increase time available for appropriate patient review as well as increase the intervention rate with patient safety benefits. [4, 5] Importantly, the clinical pharmacy workforce should also be considered and essential supporting clinical technicians included wherever feasible.
CP interventions undertaken to correct a medication error accounted for only around 40% of all interventions recorded in this study. This is a similar proportion to those found in other studies. [20, 21] The majority of interventions were optimisations or consults. The importance of these data is that it clearly demonstrates a progression in CP practice, from one historically regarded as primarily focused on detecting errors in prescribing, to one that includes consideration of evidence and individual patient variability in terms of medicines optimisation.
Several studies conducted in critically ill populations have largely demonstrated higher mortality rates associated with admission during weekends and out of hours. [22] [23] [24] [25] [26] [27] [28] The intervention rate in this study was substantially higher at weekends, with an intervention made every three prescriptions, however, the majority were optimisations. The lower than expected error detection rate at weekends, and peak on Mondays, could suggest that errors are being missed or less frequently identified at weekends, and may represent a period of increased patient risk. Of the weekend interventions, the high proportion (83.9%) of moderate or high impact graded interventions suggest that CP input at weekends is essential to reduce harm from medication errors, and optimise pharmacotherapy. This data could also demonstrate that the quality of patient care is currently diminished at the weekend in units that do not provide a weekend clinical pharmacy service.
Despite an intervention rate of more than double the weekday rate, a lower percentage of these interventions were accepted by the team. This could be attributed to a number of factors, including on-call medical staff being less familiar with patients and less confident to make changes in their medication, reduced availability of prescribers or lastly, that the CP did not always have time to complete the intervention process. Whatever the reason, developments in the number of independent pharmacist prescribers in this speciality will be expected to improve pharmacy and medical staff efficiency in this aspect. [29] Extension of critical care pharmacy services to full weekend provision, as recommended by the ICS, should be considered so that all critical care patients have access to clinical pharmacy review. This is now a future directive for both the pharmacy profession and the UK deliverers of critical care. [30] 
Implication for Future Practice and Research
The recommendation for a 7 day clinical pharmacy service is likely to be taken up in the future, with an expected impact on the types of interventions made by CPs at weekends. In addition, as more CPs apply for RPS Faculty assessment process, future work of this kind, investigating interventions and experience/competence level can be undertaken on the basis of Faculty stage rather than grading. Furthermore, the developed nature of the CP service, along with the volume and impact of the interventions described here leads one to question to what extent are these types of pharmaceutical issues addressed in critical care units without a developed CP service.
Conclusions
These results demonstrate that every patient cared for in the ICU should have daily prescription review by a CP trained in critical care. We have demonstrated that CPs reduce medication errors and optimise pharmacotherapy, with a high intervention rate per number of prescriptions reviewed. However, intervention rate is proportional to time spent reviewing a patient and thus appropriate pharmacy workforce (number and practitioner levels) levels are essential. On weekdays, optimisations and consults accounted for the majority of all interventions, with the remaining interventions involving medication error correction, demonstrating a shift in the role of the CP over the last two decades. Lastly, the higher intervention rate on the units that provided a weekend service highlights the need for clinical pharmacy services in critical care 7 days a week. In summary, this study demonstrates the need for specialist pharmacists, in sufficient numbers, to be integral to the provision of highquality critical care in the United Kingdom (UK).
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